盐酸曲美他嗪治疗2型糖尿病合并慢性心功能不全患者的临床效果分析

摘要
图/表
参考文献(19)
相关文章 (15)

全文: PDF (0 KB) HTML (37 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨盐酸曲美他嗪治疗2型糖尿病合并慢性心功能不全患者的临床效果。方法分析2014年2月～2017年2月我院门诊收治的92例2型糖尿病合并慢性心功能不全患者的临床资料，采用随机纸片法将其分为对照组（32例）和联合治疗组（60例）。对照组患者予以常规治疗，联合治疗组患者在对照组基础上，给予盐酸曲美他嗪治疗。比较两组患者治疗前后的左室射血分数（LVEF）、左心室舒张末期内径（LVEDD）、左心室收缩末期内径（LVESD）、空腹血糖（FBG）、糖化血红蛋白（HbA1c）水平及治疗后的临床效果。结果两组患者治疗前的LVEF、LVEDD、LVESD水平比较，差异无统计学意义（P＞0.05）；两组患者治疗后的LVEF水平均高于治疗前，LVEDD、LVESD水平均低于治疗前，差异均有统计学意义（P＜0.05）；联合治疗组患者治疗后的LVEF水平高于对照组，LVEDD、LVESD水平均低于对照组，差异均有统计学意义（P＜0.05）。两组患者治疗前的FBG、HbA1c水平比较，差异无统计学意义（P＞0.05）；两组患者治疗后的FBG、HbA1c水平均低于治疗前，差异均有统计学意义（P＜0.05）；联合治疗组患者治疗后的FBG、HbA1c水平均低于对照组，差异均有统计学意义（P＜0.05）。联合治疗组患者的治疗总有效率高于对照组，差异有统计学意义（P＜0.05）。两组患者于治疗期间均未出现与所用药物相关的不良反应。结论盐酸曲美他嗪治疗2型糖尿病合并慢性心功能不全患者，心功能明显改善，FBG、HbA1c水平显著降低，效果良好，值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	林少华
	陈美卿

关键词 ：盐酸曲美他嗪, 2型糖尿病, 慢性心功能不全, 心功能

Abstract：Objective To investigate the clinical effect of Trimetazidine Dihydrochloride in the treatment of patients with type 2 diabetes mellitus (DM)complicated with chronic heart failure.Methods The clinical data of 92 patients with type 2 DM and chronic heart failure treated in the outpatient of our hospital from February 2014 to February 2017 were analyzed.They were divided into control group(32 cases)and combined treatment group(60 cases)acccording to the random paper method.The control group was given conventional therapy and the combined treatment group was treated with Trimetazidine Dihydrochloride on the basis of the control group.The levels of left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),fasting blood glucose(FBG),glycosylated hemoglobin(HbA1c)before and after treatment,and clinical effect after treatment of two groups were compared.There were no significant differences in levels of LVEF,LVEDD,and LVESD between two groups before treatment(P＞0.05).The levels of LVEF in two groups after treatment were higher than that before treatment,the levels of LVEDD and LVESD were lower than those before treatment,and the differences were statistically significant(P＜0.05).The level of LVEF in the combined treatment group after treatment was higher than that in the control group,the levels of LVEDD and LVESD were lower than those in the control group,and the differences were statistically significant(P＜0.05).There were no significant differences in levels of FBG and HbA1c between two groups before treatment(P＞0.05).The levels of FBG and HbA1c in two groups after treatment were lower than those before treatment,and the difference was statistically significant(P＜0.05).The levels of FBG and HbA1c in the combined treatment group after treatment were lower than those in the control group,and the difference was statistically significant(P＜0.05).The total effective rate of treatment in the combined treatment group was higher than that in the control group,and the difference was statistically significant(P＜0.05).There were no adverse reactions related to the drug use in two groups during the treatment period.Conclusion Trimetazidine Dihydrochloride in the treatment of patients with type 2 DM complicated with chronic heart failure can significantly improve cardiac function and reduce levels of FBG and HbA1c with significant effect,which is worthy of clinical promotion and application.

Key words： Trimetazidine Dihydrochloride Type 2 diabetes mellitus Chronic heart failure Cardiac function

引用本文:

林少华;陈美卿. 盐酸曲美他嗪治疗2型糖尿病合并慢性心功能不全患者的临床效果分析[J]. 中国当代医药, 2018, 25(23): 158-161.
LIN Shao-hua;CHEN Mei-qing. Clinical effect analysis of Trimetazidine Dihydrochloride in the treatment of patients with type 2 diabetes mellitus complicated with chronic heart failure. 中国当代医药, 2018, 25(23): 158-161.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I23/158

[1]	梁静云，韦慧红.集束化护理在冠心病介入治疗患者二级预防中的效果[J].解放军预防医学杂志，2017，35（7）：820-821，836.
[2]	朱蕾.辛伐他汀联合盐酸曲美他嗪治疗糖尿病合并冠心病的临床疗效分析[J].中西医结合心血管病杂志，2017，5（3）：23.
[3]	张培培，黄榕.曲美他嗪治疗糖尿病合并慢性心功能不全患者的临床疗效观察[J].安徽医药，2018，22（2）：348-351.
[4]	廖清池，宋学璟，李琪，等.芪参益气滴丸联合曲美他嗪治疗糖尿病合并缺血性心肌病心力衰竭的疗效观察[J].中西医结合心血管病杂志，2017，5（24）：96-97.
[5]	中华医学会糖尿病学分会.中国2型糖尿病防治指南（2013 年版）[J].中华糖尿病杂志，2014，6（7）：447-498.
[6]	中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志，2014，42（2）：98-122.
[7]	张莉，王秀琼.曲美他嗪治疗糖尿病伴冠心病患者的临床疗效[J].中国当代医药，2016，23（5）：125-127.
[8]	阿卜杜热西提?则亚维丁.冠心病合并糖尿病患者采用曲美他嗪治疗对其心绞痛持续时间的影响分析[J].中西医结合心血管病杂志，2016，4（32）：46.
[9]	张淑娟.曲美他嗪治疗冠心病合并糖尿病的临床应用效果分析[J].中西医结合心血管病杂志，2016，4（31）：93.
[10]	Gelosa P，Banfi C，Brioschi M.S35171 exerts protective effects in spontaneously hypertensive stroke-prone rats by preserving mitochondrial function[J].Eur J Pharmacol，2009，604（1-3）：117-124.
[11]	梁俊文，郭志强，林嘉敏，等.曲美他嗪对糖尿病性心肌病大鼠心肌损伤保护作用研究[J].现代中西医结合杂志，2015，24（13）：1378-1380.
[12]	Morozova TE，Ivanova EP，Rykova SM.Clinico-economical aspects of application of trimetazidine MB in patients with chronic heart failure and cardiac rhythm disturbances[J].Kardiologiia，2011，51（9）：35-41.
[13]	彭玉娟，谢亚芹，康大伟，等.曲美他嗪与雷米普利对慢性心力衰竭大鼠心肌组织转化生长因子β1表达的影响[J].中华老年心脑血管病杂志，2014，16（1）：21-24.
[14]	申丽锋，詹文彦，田国芳，等.保心安胶囊联合曲美他嗪片对2型糖尿病合并心力衰竭患者pro-BNP的影响研究[J].河北医药，2018，40（2）：183-187.
[15]	李雪霖，何金，田卓，等.Tei指数评价曲美他嗪治疗糖尿病心肌病慢性心力衰竭的临床研究[J].临床超声医学杂志，2017，19（7）：437-439.
[16]	Park JJ，Choi DJ，Yoon CH，et al.Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure （from the Korean Heart Failure Registry）[J].Am J Cardiol，2014，113（3）：511-517.
[17]	Den Engelsen C，Koekkoek PS，Gorter KJ，et al.High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population：a cross-sectional analysis[J].Cardiovasc Diabetol，2012，11（1）：25.
[18]	吴静.曲美他嗪治疗糖尿病合并冠心病的临床分析[J].中西医结合心血管病杂志，2015，3（32）：111-113.
[19]	Rantor PF，Lucien A，Kozak R，et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain-3-ketoacyl coennzyme A thiolase[J].Circ Res，2000，86（5）：580-588.